We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Evosep and Agilent Collaborate to Improve Proteomics Workflows

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Evosep and Agilent Collaborate to Improve Proteomics Workflows"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

At the ASMS 2020 Reboot, Evosep and Agilent Technologies have announced their joint efforts to improve robust, high-throughput workflows for clinical research proteomics. The initial data from the collaboration was presented at the conference in poster ThP 489 as well as in an online webinar.

Mass spectrometry (MS)-based proteomics has become a central technology in biological research and it is now promising to become equally powerful for future clinical research, for instance through characterization of the plasma proteome and tissue proteomes in adequate depth. Proteomics as a technology may have lacked the speed and robustness necessary, but with recent advances in sample preparation and chromatography, accurate proteome quantitation in high throughput mode for thousands of samples is now possible.

Dr Nicolai Bache, Head of Application, Evosep elaborates: “The Evosep One separation solution fits perfectly with the routine focused applications developed by Agilent Technologies by enabling really high throughput sample separation for MS analyses while still being extremely easy to use for the customer. The combination of an Evosep One and an Agilent Technologies Mass Spectrometer, e.g. a triple Quadrupole, will enable ultra-robust, sensitive and fully automated workflows. What every lab would want and an important step forward for clinical research.”